INTO GERMANY is the German business podcast in the English language.
Every month we take a fast-paced but in-depth look at one of the hottest sectors and round up some of the most intriguing stories from Europe’s largest economy.
Whether you’re an international businessperson already into Germany or just curious about EXPANDING your company to the heart of the EU, we’ve got lots of on-the-ground success stories. Plus some helpful hints about how Germany works – and could work for you.
So tune in every month to INTO GERMANY! Because Germany means business.
Send feedback and comments to andreas.bilfinger@gtai.com
A podcast by Germany Trade & Invest.
Germany Trade & Invest (GTAI) is the economic development agency of the Federal Republic of Germany.
You can find more information on https://www.gtai.de/en/invest
All content for INTO GERMANY! The German Business Podcast is the property of Germany Trade & Invest - GTAI and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
INTO GERMANY is the German business podcast in the English language.
Every month we take a fast-paced but in-depth look at one of the hottest sectors and round up some of the most intriguing stories from Europe’s largest economy.
Whether you’re an international businessperson already into Germany or just curious about EXPANDING your company to the heart of the EU, we’ve got lots of on-the-ground success stories. Plus some helpful hints about how Germany works – and could work for you.
So tune in every month to INTO GERMANY! Because Germany means business.
Send feedback and comments to andreas.bilfinger@gtai.com
A podcast by Germany Trade & Invest.
Germany Trade & Invest (GTAI) is the economic development agency of the Federal Republic of Germany.
You can find more information on https://www.gtai.de/en/invest
A Shot in the Arm: Pharma Benefits from a New German Legal
INTO GERMANY! The German Business Podcast
25 minutes
1 year ago
A Shot in the Arm: Pharma Benefits from a New German Legal
In late 2023, American pharma giant Eli Lilly and Company announced plans to build a $2.5 billion production facility in western Germany. It’s one of the largest investments in the sector ever. The plant will at first produce its new tirzepatide drugs for diabetes and obesity. Demand is expected to soar. The major expansion comes as Berlin is reforming the rules governing German pharma, with a key aim of boosting drug production within the country.
Our Guests:
Gerd Kräh is associate VP of government affairs with Eli Lilly Deutschland. He is one of the most experienced media and political affairs executives in the German pharmaceutical industry.
Marcus Schmidt is director of the chemicals and health division at Germany Trade & Invest. He has worked as an advisor to the German government on reforming policies regulating the pharmaceutical sector, and helped Eli Lilly and Company find a location in Germany to build one of its largest plants outside of the United States.
INTO GERMANY! The German Business Podcast
INTO GERMANY is the German business podcast in the English language.
Every month we take a fast-paced but in-depth look at one of the hottest sectors and round up some of the most intriguing stories from Europe’s largest economy.
Whether you’re an international businessperson already into Germany or just curious about EXPANDING your company to the heart of the EU, we’ve got lots of on-the-ground success stories. Plus some helpful hints about how Germany works – and could work for you.
So tune in every month to INTO GERMANY! Because Germany means business.
Send feedback and comments to andreas.bilfinger@gtai.com
A podcast by Germany Trade & Invest.
Germany Trade & Invest (GTAI) is the economic development agency of the Federal Republic of Germany.
You can find more information on https://www.gtai.de/en/invest
